Free Trial
OTCMKTS:BICX

BioCorRx (BICX) Stock Price, News & Analysis

BioCorRx logo
$0.41 +0.06 (+17.86%)
As of 03/28/2025 03:00 PM Eastern

About BioCorRx Stock (OTCMKTS:BICX)

Key Stats

Today's Range
$0.37
$0.41
50-Day Range
$0.26
$1.00
52-Week Range
$0.26
$1.50
Volume
21,208 shs
Average Volume
14,262 shs
Market Capitalization
$6.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

Remove Ads

BioCorRx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
5th Percentile Overall Score

BICX MarketRank™: 

BioCorRx scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for BioCorRx.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioCorRx is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioCorRx is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about BioCorRx's valuation and earnings.
  • Percentage of Shares Shorted

    0.06% of the float of BioCorRx has been sold short.
  • Short Interest Ratio / Days to Cover

    BioCorRx has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioCorRx has recently increased by 222.73%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    BioCorRx does not currently pay a dividend.

  • Dividend Growth

    BioCorRx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.06% of the float of BioCorRx has been sold short.
  • Short Interest Ratio / Days to Cover

    BioCorRx has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioCorRx has recently increased by 222.73%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    BioCorRx has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for BioCorRx this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, BioCorRx insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.40% of the stock of BioCorRx is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about BioCorRx's insider trading history.
Receive BICX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCorRx and its competitors with MarketBeat's FREE daily newsletter.

BICX Stock News Headlines

AI Boom Takes a Shocking Turn…
AI is Creating Fortunes… (but not where you think!) Bryce Paul and the team at Crypto101 just released a brand-new report…
BioCorRx Inc. (BICX)
See More Headlines

BICX Stock Analysis - Frequently Asked Questions

BioCorRx's stock was trading at $0.38 at the beginning of 2025. Since then, BICX shares have increased by 8.6% and is now trading at $0.4125.
View the best growth stocks for 2025 here
.

BioCorRx Inc. (OTCMKTS:BICX) issued its quarterly earnings results on Thursday, November, 17th. The company reported ($0.02) EPS for the quarter. The business earned $0.17 million during the quarter.

Shares of BICX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioCorRx investors own include PlayAGS (AGS), Ashford Hospitality Trust (AHT), Peabody Energy (BTU), Mondi (MNDI), Assertio (ASRT), Astronics (ATRO) and CONSOL Coal Resources (CCR).

Company Calendar

Last Earnings
11/17/2016
Today
3/31/2025
Next Earnings (Estimated)
3/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Specialty outpatient clinics, not elsewhere classified
Sub-Industry
Healthcare
Current Symbol
OTCMKTS:BICX
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-3,770,000.00
Net Margins
-11,600.00%
Pretax Margin
-18,340.74%

Debt

Sales & Book Value

Annual Sales
$90,000.00
Price / Cash Flow
N/A
Book Value
($1.14) per share
Price / Book
-0.36

Miscellaneous

Free Float
11,920,000
Market Cap
$6.64 million
Optionable
Not Optionable
Beta
0.57

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (OTCMKTS:BICX) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners